HIV-associated neurological disorders: a guide to pharmacotherapy.

Authors:
Ik L Tan
Ik L Tan
Johns Hopkins School of Medicine
Baltimore | United States
Justin C McArthur
Justin C McArthur
Johns Hopkins University
Baltimore | United States

CNS Drugs 2012 Feb;26(2):123-34

Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD 21287-7613, USA.

In the era of highly active antiretroviral therapy (HAART), HIV-1-associated neurocognitive disorder (HAND) continues to be a common and significant morbidity among individuals infected with HIV. The term HAND encompasses a spectrum of progressively severe CNS involvement, ranging from asymptomatic neurocognitive impairment and minor neurocognitive disorder through to the most severe form of HIV-associated dementia (HAD). While the incidence of HAD has declined significantly with HAART, the milder forms of HAND persist. In addition, HAND now develops in individuals with less advanced immunosuppression. The reasons for the persistence of milder forms of HAND in individuals treated with HAART are not entirely known. There are several hypotheses to explain this phenomenon that include the legacy effect, a failure of antiretroviral agents to reverse neurological damage, poor access of antiretroviral agents to the CNS, chronic systemic immune activation associated with microbial translocation products, sustained CNS inflammation, the improved survival of HIV-seropositive individuals and the possible contribution from aging, amyloid deposition and other co-morbidities. In contrast, the incidence of HIV-associated CNS opportunistic processes including progressive multifocal leukoencephalopathy, tuberculosis, CNS toxoplasmosis, cytomegalovirus encephalitis, cryptococcosis and primary CNS lymphoma has declined dramatically with the introduction of HAART. This review briefly summarizes our current understanding of HAND and the pathological mechanisms involved, namely direct injury from HIV-1 and viral proteins, indirect neurotoxicity from proinflammatory cytokines and chronic, sustained immune activation in the CNS. To date, only HAART has been shown to benefit HAND despite numerous controlled trials of adjunctive 'anti-inflammatory' agents. Although HAART has a profound impact on the incidence and severity of HAND, there exists a 'therapeutic gap' as even HAART that is effective at inducing durable virological suppression may only partially reverse HAND. In addition, there may be potential CNS adverse effects of antiretroviral agents. There is an ongoing multicentre clinical trial to investigate the role of the CNS Penetration-Effectiveness index, an indicator of drug permeability and availability in the CNS, to help guide the choice of antiretroviral agents in the treatment of HAND. With recent recommendations for earlier treatment intervention with HAART for HIV-1 infection, it remains to be seen the effects of this on HAND. There is an urgent need to better define the therapeutic guidelines for the prevention and treatment of HAND.

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.2165/11597770-000000
Web Search
http://link.springer.com/10.2165/11597770-000000000-00000
Publisher Site
http://dx.doi.org/10.2165/11597770-000000000-00000DOI Listing
February 2012
21 Reads

Publication Analysis

Top Keywords

antiretroviral agents
16
hand
12
cns
10
haart
8
neurocognitive disorder
8
forms hand
8
treatment hand
8
milder forms
8
immune activation
8
antiretroviral
5
agents
5
trial investigate
4
individuals contribution
4
contribution aging
4
benefit hand
4
aging amyloid
4
hiv-seropositive individuals
4
survival hiv-seropositive
4
inflammation improved
4
hand despite
4

References

(Supplied by CrossRef)
Article in Lancet
Lancet 2008 Jul 26
Article in AIDS
Simioni et al.
AIDS 2010 Jun 1
Article in J Neurovirol
Cysique et al.
J Neurovirol 2004 Dec
Article in Lancet Neurol
McArthur et al.
Lancet Neurol 2005 Sep
Article in Ann Neurol
McArthur et al.
Ann Neurol 2010 Jun
Article in Neurology
Antinori et al.
Neurology 2007 Oct 30
Article in J Neuroimmunol
McArthur et al.
J Neuroimmunol 2004 Dec
Article in Clin Geriatr Med
Luther et al.
Clin Geriatr Med 2007 Aug
Article in Neurology
Sevigny et al.
Neurology 2004 Dec 14
Article in Neurology
Cysique et al.
Neurology 2006 May 9
Article in Top HIV Med
Clifford et al.
Top HIV Med 2008 Jun-Jul

Similar Publications